Gilead Compares Stribild To Prezista In Seeking Exclusivity For Fixed Dose Combinations

Gilead requests five-year marketing exclusivity for two of the components in its HIV Quad treatment Stribild; citizen petition says award should not depend on whether a new active moiety is approved first as a single entity product or as part of a fixed-dose combination.